National Cancer Institute Selects SRI Treatment for Prostate Cancer | SRI International

Toggle Menu

SRI International Cancer Drug SR 16388 Selected by the National Cancer Institute as Promising Treatment for Advanced Prostate Cancer

MENLO PARK, Calif. – June 20, 2007 – SRI International, an independent nonprofit research and development organization, today announced that SRI has received support through the Rapid Access to Intervention Development (RAID) program of the National Cancer Institute (NCI).  Approved applications to RAID gain access to the drug development resources of the Developmental Therapeutics Program.  These resources will be used to further the preclinical development of SRI’s drug SR16388 to treat advanced cancers. This novel antiangiogenic drug is currently in development for the treatment of multiple tumor types including metastatic prostate cancer.       

"SR16388 is the third SRI drug candidate to be awarded  development support from the National Cancer Institute," said Nathan Collins, Ph.D, executive director of drug discovery in SRI's Biosciences Division. "This latest award demonstrates the broad capabilities of SRI as a premier research and development organization with a strong drug pipeline. We are dedicated to the development of innovative solutions that will ultimately reach patients and improve their lives."

SR16388 is a novel drug for the inhibition of angiogenesis in tumors.  Angiogenesis is the mechanism by which new blood vessels grow in tumors to support continued cancer growth.  The drug binds estrogen receptor beta, and inhibits activation of transcription factors STAT3 and HIF-1 that together regulate pathways for cancer cell survival, proliferation, vascularization and metastasis. Its potent antiangiogenic and anti-invasive activities include direct effects on microvascular endothelial cells and on the tumor microenvironment.

The NCI RAID program is a peer-reviewed competitive award program designed to assist translation of novel anticancer therapeutics to the clinic.  The goal of the program is to show proof of principle that a new molecule is a viable candidate for expanded clinical evaluation. 

In 2003, SRI received RAID support for SR16157, a novel, dual-targeted steroidal sulfatase inhibitor and antiestrogen for the treatment of advanced breast cancer.   Also in 2003, SRI received funding for SR13668, a novel inhibitor of the AKT pathway, under the sponsorship of NCI's RAPID (Rapid Access to Preventive Intervention Development) competitive award grant program.

About SRI's Biosciences Division

SRI International’s Biosciences Division is an organization of approximately 200 people with all of the resources necessary to take biological and chemical research programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials. SRI Biosciences conducts basic research like a university, performs drug discovery and develops biologics like a biotechnology company, and is a contract research organization (CRO) that offers a full range of preclinical development and pharmaceutical sciences services. SRI Biosciences specializes in cancer, immunology, infectious disease, and neurosciences research. 

To date, SRI has developed nine drugs internally that have entered clinical trials, with several more currently undergoing preclinical evaluation. Marketed examples of these drugs include Targretin® (bexarotene) and Halfan® (halofantrine). Additionally, working with government and industry partners, SRI has helped advance on the order of 150 drugs into clinical trials, and more than 10 drugs onto the market. Through collaborations with other divisions at SRI, Biosciences is also working at the interfaces of science to create technical platforms for the next generation of drug discovery and development in areas such as drug delivery, devices, diagnostics, and systems biology.

About SRI International
Silicon Valley-based SRI International ( is one of the world’s leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.